← All organizations
Highest phase reached
Phase 3
First clinical trial
Oct 1, 1999Last known activity
Apr 1, 2022
Timeline
1960s
- Jan 1, 1962
Fondation ARC— Founded
Drugs by trial phase (50 distinct, 17 trials)
Phase 3 (8 own, 0 via acquisition)
Phase 2 (42 own, 0 via acquisition)
Indications
Studied for
- Anus Neoplasms
- Breast Neoplasms
- Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Squamous Cell
- Disease Progression
- Glioblastoma
- Head and Neck Neoplasms
- Hematologic Neoplasms
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Lung Neoplasms
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Myelodysplastic Syndromes
- Neoplasm Metastasis
- Neoplasms
- Penile Neoplasms
- Preleukemia
- Rectal Neoplasms
- Sarcoma
- Squamous Cell Carcinoma of Head and Neck
- Uterine Cervical Neoplasms
- Vulvar Neoplasms
Recent trials (17)
- NCT05210413CollaboratorPhase 1/Phase 2Apr 1, 2022
- NCT04357873CollaboratorPhase 2Jul 31, 2020
- NCT04263051CollaboratorPhase 2Apr 1, 2020
- NCT03951337CollaboratorPhase 2Apr 26, 2019
- NCT03386929CollaboratorPhase 1/Phase 2Nov 29, 2017
- NCT02505048CollaboratorPhase 2Mar 1, 2016
- NCT02630368CollaboratorPhase 1/Phase 2Sep 1, 2015
- NCT02438761CollaboratorPhase 2Aug 31, 2015
- NCT02364206CollaboratorPhase 1/Phase 2Jun 1, 2015
- NCT02322853CollaboratorPhase 2Jan 1, 2015
- NCT02304809CollaboratorPhase 2Jul 1, 2014
- NCT02117167CollaboratorPhase 2Apr 23, 2014
- NCT02299999CollaboratorPhase 2Apr 7, 2014
- NCT02034981CollaboratorPhase 2Aug 1, 2013
- NCT01737450CollaboratorPhase 2Jan 1, 2013
Details
- Founded
- Villejuif, FR Jan 1, 1962
- Last known activity
- Apr 1, 2022